LIPA and cancer: Among these genes, 33 (16%; referring to 200 gene‐cancer pairs) were under clinical trial evaluation; 23 of 33 (70%) were anticancer drug targets; 23 of 33 (70%) are still active or complete in clinical trials, with drugs targeting four genes, LIPA, MAP2K1, PSMB5 and NDUFB3 already having been launched for treatment of cancers or diabetes.